{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:50:51Z","timestamp":1792479051834,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK056008"],"award-info":[{"award-number":["DK056008"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK108648"],"award-info":[{"award-number":["DK108648"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK117058"],"award-info":[{"award-number":["K23DK117058"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R03DK129631"],"award-info":[{"award-number":["R03DK129631"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cgh.2023.08.039","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:36:44Z","timestamp":1694752604000},"page":"22-33.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"22","author":[{"given":"David J.","family":"Katibian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Solitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Brent","family":"Polk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Syal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sine","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Andrew","family":"Ainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-7269","authenticated-orcid":false,"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.08.039_bib1","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice Guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.08.039_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG Clinical Guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.08.039_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.08.039_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"SONIC Study Group Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.08.039_bib5","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.cgh.2018.11.003","article-title":"Upfront combination therapy, compared with monotherapy, for patients not previously treated with a biologic agent associates with reduced risk of inflammatory bowel disease-related complications in a population-based cohort study","volume":"17","author":"Targownik","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bib6","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjaa050","article-title":"Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications","volume":"14","author":"Targownik","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.08.039_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.08.039_bib8","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2023.08.039_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"COIN study group and the Dutch Initiative on Crohn and Colitis Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2023.08.039_bib11","doi-asserted-by":"crossref","first-page":"A5","DOI":"10.1136\/gutjnl-2015-309861.9","article-title":"Withdrawal of anti-TNF following sustained remission for inflammatory bowel disease: a systematic review and meta-analysis","volume":"64","author":"Kennedy","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.08.039_bib12","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.cgh.2022.01.019","article-title":"Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease","volume":"20","author":"Mahmoud","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bib13","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","article-title":"Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease","volume":"149","author":"Torres","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.08.039_bib14","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.08.039_bib15","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MPG.0000000000000684","article-title":"Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease","volume":"60","author":"Kierkus","year":"2015","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2023.08.039_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.08.039_bib17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00535-019-01582-w","article-title":"Withdrawal of thiopurines in Crohn\u2019s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)","volume":"54","author":"Hisamatsu","year":"2019","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2023.08.039_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2468-1253(21)00062-5","article-title":"Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial","volume":"6","author":"Kobayashi","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bib19","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200061","article-title":"the Stop Infliximab Treatment (STOP-IT) Study Group. Discontinuation of infliximab therapy in patients with Crohn\u2019s disease","volume":"1","author":"Buhl","year":"2022","journal-title":"NEJM Evidence"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2023.08.039_bib20","doi-asserted-by":"crossref","first-page":"i50","DOI":"10.1093\/ecco-jcc\/jjac190.0037","article-title":"Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)","volume":"17","author":"Chapparo","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.08.039_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"GETAID and the SPARE-Biocycle research group. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn\u2019s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bib22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2023.08.039_bib23","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2023.08.039_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.cgh.2023.08.039_bib25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2023.08.039_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2023.08.039_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cgh.2023.08.039_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211041927","article-title":"Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Yang","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.cgh.2023.08.039_bib29","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.08.039_bib30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.08.039_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S2468-1253(19)30186-4","article-title":"De-escalation of immunomodulator and biological therapy in inflammatory bowel disease","volume":"5","author":"Chapman","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and Colitis Organisation topical review on treatment withdrawal [\u2018exit strategies\u2019] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.08.039_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.03.044","article-title":"HLA-DQA1 \u221705 genotype and immunogenicity to tumor necrosis factor-alpha antagonists: a systematic review and meta-analysis","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2023.08.039_bib34","doi-asserted-by":"crossref","first-page":"i542","DOI":"10.1093\/ecco-jcc\/jjac190.0543","article-title":"Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): a multi-center randomized controlled trial","volume":"17","author":"Pudipeddi","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.08.039_bib35","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/j.cgh.2022.10.016","article-title":"Combination therapy with immunomodulators improves the pharmacokinetics of infliximab but not vedolizumab or ustekinumab","volume":"21","author":"Yarur","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bib36","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.cgh.2023.01.041","article-title":"To combine or not to combine: do we need concomitant immunomodulators when using non-TNF-targeting biologics?","volume":"21","author":"Singh","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bib37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"UK Inflammatory Bowel Disease Pharmacogenetics Study Group. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bib38","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cgh.2021.03.037","article-title":"Prediction of relapse after anti-tumor necrosis factor cessation in Crohn\u2019s disease: individual participant data meta-analysis of 1317 patients from 14 studies","volume":"20","author":"Pauwels","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bibe1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.08.039_bibe2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MPG.0000000000000684","article-title":"Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease","volume":"60","author":"Kierkus","year":"2015","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2023.08.039_bibe3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.08.039_bibe4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00535-019-01582-w","article-title":"Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)","volume":"54","author":"Hisamatsu","year":"2019","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2023.08.039_bibe5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2468-1253(21)00062-5","article-title":"Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial","volume":"6","author":"Kobayashi","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bibe6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200061","article-title":"Discontinuation of infliximab therapy in patients with Crohn\u2019s disease","volume":"1","author":"Buhl","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.cgh.2023.08.039_bibe7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"GETAID and the SPARE-Biocycle research group. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn\u2019s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.08.039_bibe8","doi-asserted-by":"crossref","first-page":"i50","DOI":"10.1093\/ecco-jcc\/jjac190.0037","article-title":"Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)","volume":"17","author":"Chapparo","year":"2023","journal-title":"J\u00a0Crohns Colitis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523007097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523007097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:44:28Z","timestamp":1761543868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523007097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1542356523007097"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.08.039","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute","name":"copyright","label":"Copyright"}]}}